Doximity: Resilient Fundamentals and AI-Driven Growth Support Buy Rating Despite Temporary Pharma Budget Delays

William Blair analyst Ryan Daniels has maintained their bullish stance on DOCS stock, giving a Buy rating on February 4.

Ryan Daniels has given his Buy rating due to a combination of factors that highlight Doximity’s solid underlying performance and favorable long-term positioning despite near-term headwinds. He notes that the company delivered double-digit revenue growth and meaningfully exceeded consensus expectations on profitability, demonstrating strong operational execution and attractive margins. While fourth-quarter guidance is softer, largely because some large pharmaceutical clients took longer than usual to finalize their marketing budgets amid policy-related timing issues, Daniels views this as a timing shift rather than a structural deterioration in demand.
At the same time, management reaffirmed its full-year revenue outlook and continues to anticipate mid-single-digit growth in overall pharma marketing budgets for 2026, which aligns with Daniels’s view of a stable end market. He also highlights Doximity’s strong engagement metrics and its expanding suite of workflow and AI-driven tools, which should support continued upsell opportunities as delayed budgets are released over the year. The planned investments in AI are expected to weigh modestly on short-term margins, but Daniels believes they will enhance the platform’s competitiveness and monetization potential over time. Taken together, he concludes that the combination of resilient fundamentals, temporary nature of current budget delays, and compelling long-term growth drivers justifies maintaining a Buy rating on the stock.

In another report released on February 4, TipRanks – OpenAI also reiterated a Buy rating on the stock with a $39.00 price target.